Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

249,00 € / $374.00 / £187.00*

See all formats and pricing


Select Volume and Issue


The human epidermal growth factor receptor 2 (HER2)

1 / Gregory J. Tsongalis1

1Department of Pathology, Dartmouth Medical School, Dartmouth Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH, USA

Corresponding author: Laura J. Tafe, MD, Department of Pathology, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA Phone: +1-603-650-7211, Fax: 1-603-650-7214

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 50, Issue 1, Pages 23–30, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/cclm.2011.707, September 2011

Publication History

Published Online:


The declared “war on cancer” aimed to eradicate this disease using our knowledge of cancer cell biology to develop novel therapeutics. One such target of these novel therapies has been the human epidermal growth factor receptor 2 (HER2) gene. Unique in the approach to abolishing function of this gene coded receptor, it was the first target of new monoclonal antibody therapy targeting the extracellular receptor and now also a target of small molecule drugs against the intracellular tyrosine kinase domain. In this instance, it was also one of the first applications of personalized medicine requiring companion diagnostics. In this manuscript, we review the biology and clinical applications of HER2 as a biomarker of disease and as a therapeutic target.

Keywords: breast cancer; gastric cancer; Her2; lapatinib; trastuzumab

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Peppino Mirabelli and Mariarosaria Incoronato
BioMed Research International, 2013, Volume 2013, Page 1
Ashley G. Rivenbark, Siobhan M. O’Connor, and William B. Coleman
The American Journal of Pathology, 2013, Volume 183, Number 4, Page 1113
Jolieke G. van Oosterwijk, Jakob K. Anninga, Hans Gelderblom, Anne-Marie Cleton-Jansen, and Judith V.M.G. Bovée
Hematology/Oncology Clinics of North America, 2013, Volume 27, Number 5, Page 1021

Comments (0)

Please log in or register to comment.